SNCAIP Gene

SNCAIP Gene — Synphilin-1 (Alpha-Synuclein Interacting Protein)

Pathway Diagram

```mermaid
flowchart TD
SNCAIP["SNCAIP<br/>(Synphilin-1)"]
SNCA["SNCA<br/>(alpha-synuclein)"]
PARKIN["PARKIN<br/>(E3 ubiquitin ligase)"]
PRKN["PRKN<br/>(Parkin RBR E3<br/>ubiquitin ligase)"]

RB1CC1["RB1CC1<br/>(FIP200/<br/>autophagy initiator)"]
LC3["LC3<br/>(autophagosome<br/>marker)"]
FAM134B["FAM134B<br/>(ER-phagy<br/>receptor)"]

MFN1["MFN1<br/>(mitochondrial<br/>fusion)"]
MIRO1["MIRO1<br/>(mitochondrial<br/>transport)"]
ERN1["ERN1<br/>(ER stress<br/>sensor)"]

CTSD["CTSD<br/>(cathepsin D/<br/>lysosomal enzyme)"]
BCL2L11["BCL2L11<br/>(BIM/<br/>pro-apoptotic)"]

PD["Parkinson's<br/>Disease"]
AD["Alzheimer's<br/>Disease"]
ALS["Amyotrophic<br/>Lateral Sclerosis"]
FTD["Frontotemporal<br/>Dementia"]

ProteinAgg["Protein<br/>Aggregation"]
Autophagy["Autophagy<br/>Dysfunction"]
MitoStress["Mitochondrial<br/>Dysfunction"]

SNCAIP -->|"forms inclusions with"| SNCA
SNCAIP -->|"interacts with"| PARKIN
SNCAIP -->|"interacts with"| PRKN

SNCAIP -->|"regulates"| RB1CC1
RB1CC1 -->|"initiates"| LC3
SNCAIP -->|"modulates"| FAM134B

SNCAIP -->|"affects"| MFN1
SNCAIP -->|"influences"| MIRO1
SNCAIP -->|"responds to"| ERN1

SNCAIP -->|"processed by"| CTSD
SNCAIP -->|"activates"| BCL2L11

SNCA -->|"contributes to"| ProteinAgg
PARKIN -->|"dysfunction leads to"| Autophagy
MFN1 -->|"dysfunction causes"| MitoStress

ProteinAgg -->|"

SNCAIP Gene — Synphilin-1 (Alpha-Synuclein Interacting Protein)

Pathway Diagram

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SNCAIP Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SNCAIP</td></tr>
<tr><td><strong>Full Name</strong></td><td>Synphilin-1 (Alpha-Synuclein Interacting Protein)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5q23.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10407](https://www.ncbi.nlm.nih.gov/gene/10407)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[603516](https://www.omim.org/entry/603516)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000145341</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O60341](https://www.uniprot.org/uniprot/O60341)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>777 amino acids</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Scaffold protein, alpha-synuclein interactor</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/lewy-body-dementia), [Multiple System Atrophy](/diseases/multiple-system-atrophy)</td></tr>
</table>
</div>

Overview

SNCAIP (Synphilin-1) encodes a protein that was originally identified through its direct interaction with [alpha-synuclein](/proteins/alpha-synuclein), the protein that forms the characteristic Lewy bodies in [Parkinson's Disease](/diseases/parkinsons-disease) and related synucleinopathies[@chung2001]. Synphilin-1 is a 777-amino acid protein that plays critical roles in protein aggregation, degradation pathways, and neuronal survival. It has emerged as an important player in the pathogenesis of neurodegenerative diseases, particularly those involving alpha-synuclein pathology.

The protein serves multiple functions in the nervous system, acting as a scaffold that brings together various proteins involved in protein quality control, synaptic function, and cell death pathways. SNCAIP mutations and variants have been associated with increased risk of Parkinson's disease, particularly in combination with SNCA (alpha-synuclein) multiplications[@wszolek2012][@xie2015].

Discovery and Nomenclature

SNCAIP was first identified in 2001 through yeast two-hybrid screening as a protein that directly interacts with alpha-synuclein[@chung2001]. The gene name reflects its identity as the "alpha-synuclein interacting protein." Synphilin-1 (a contraction of "synuclein/philin") highlights its relationship to synuclein family proteins.

Protein Structure and Function

Domain Architecture

Synphilin-1 contains several distinctive structural domains:

Key Functional Properties

Alpha-Synuclein Interaction

Synphilin-1 binds directly to alpha-synuclein through:

• Central region interaction (aa 100-300)
• Coiled-coil domain involvement
• The interaction is believed to be phosphorylation-dependent

• Co-aggregation of both proteins into Lewy bodies
• Formation of toxic oligomers
• Sequestration of proteins into inclusions
• Template for spreading pathology

SNARE Complex Interactions

Synphilin-1 interacts with the SNARE machinery[@rubio2012]:

• Direct binding to SNAP25
• Modulation of SNARE complex assembly
• Regulation of neurotransmitter release
• Connection to synaptic vesicle cycling

Ubiquitination Pathway

Synphilin-1 is subject to ubiquitination by multiple E3 ligases[@kahns2013][@fan2006]:

• SIAH-1 (Seven in Absentia Homolog 1): Promotes proteasomal degradation
• Parkin: E3 ligase mutated in familial PD
• Other ligases: Contribute to quality control

Expression Pattern

Brain Regional Distribution

SNCAIP shows characteristic expression in the nervous system:

• Substantia nigra: High expression in dopaminergic neurons
• Cerebral cortex: Strong expression in all cortical layers
• Hippocampus: Particularly in CA regions and dentate gyrus
• Striatum: Moderate expression in medium spiny neurons
• Cerebellum: Lower expression in Purkinje cells

Cellular and Subcellular Localization

• Cytosolic: Major cellular compartment
• Membrane-associated: Synaptic vesicle fractions
• Synaptic terminals: Enriched in presynaptic compartments
• Lewy bodies: Co-localizes with alpha-synuclein inclusions

SNCAIP in Parkinson's Disease

Genetic Associations

SNCAIP variants modify PD risk through several mechanisms[@wszolek2012][@xie2015][@kim2018]:

• S481A variant: Associated with increased PD risk in SNCA multiplication carriers
• Other coding variants: May affect protein function
• Promoter variants: May alter expression levels

Lewy Body Pathology

Synphilin-1 is a major component of Lewy bodies[@tanji2010][@wang2017]:

• Co-localizes with alpha-synuclein in classic Lewy bodies
• Present in cortical and brainstem Lewy bodies
• Found in both sporadic and familial PD cases
• May serve as a scaffold for inclusion formation

Aggregation Mechanisms

Synphilin-1 promotes alpha-synuclein aggregation through[@fujita2018][@bjorklund2019]:

Protein Degradation Pathways

Impaired degradation contributes to accumulation[@zhang2014][@nixon2005]:

• Ubiquitin-proteasome system: Primary degradation pathway
• SIAH-1 mediated: E3 ligase targeting for proteasome
• Autophagy-lysosome pathway: May handle larger aggregates
• Impaired clearance: Contributes to aggregate accumulation

Disease Associations

Parkinson's Disease

SNCAIP is directly linked to PD pathogenesis:

• Genetic risk: Variants modify disease risk
• Lewy body component: Major structural element
• Pathogenic mechanisms: Multiple, including aggregation and degradation
• Therapeutic target: Promising for intervention

Dementia with Lewy Bodies

• Synphilin-1 inclusions in DLB brain
• Interacts with alpha-synuclein strains
• Contributes to cortical pathology

Multiple System Atrophy

• Less prominent synphilin-1 pathology
• Distinct aggregation mechanisms
• May differ from PD/DLB

Other Neurodegenerative Conditions

• Incidental Lewy body disease: Preclinical stage
• Parkinsonism-plus syndromes: Variable involvement

Molecular Interactions in Detail

Protein Quality Control Network

Synphilin-1 interacts with multiple quality control proteins:

• SIAH-1: E3 ubiquitin ligase for degradation
• Parkin: PD-associated E3 ligase
• Ubiquitin: Conjugation to target proteins
• Proteasome subunits: Degradation machinery
• HSP70: Molecular chaperone

Signaling Pathways

Synphilin-1 intersects with several signaling pathways:

• Apoptosis pathways: Modulation of cell death
• Dopamine signaling: Regulation of neurotransmission
• Mitochondrial function: Effects on energy metabolism
• Calcium homeostasis: Synaptic calcium regulation

Synaptic Function

Synphilin-1 participates in synaptic biology[@eng2006][@sato2019]:

• Synaptic vesicle cycling: Regulates release
• SNARE complex assembly: Modulates fusion
• Dopamine release: Particularly in striatal neurons
• Synaptic plasticity: Activity-dependent changes

Therapeutic Implications

Aggregation Inhibitors

Targeting the SNCAIP-SNCA interaction:

• Peptide inhibitors: Block protein-protein interaction
• Small molecules: Prevent complex formation
• Antibody-based: Target interaction domains

Ubiquitination Modulators

Enhancing protein clearance:

• SIAH-1 inhibitors: Prevent excessive degradation
• Proteasome enhancers: Promote aggregate clearance
• Combination approaches: Multiple mechanisms

Gene Therapy Approaches

• RNAi: Reduce SNCAIP expression
• CRISPR editing: Correct risk variants
• Gene replacement: Not applicable (gain-of-function)

Small Molecule Development

Promising therapeutic strategies:

• Alpha-synuclein aggregation blockers: May act on SNCAIP interaction
• SIAH-1 modulators: Alter degradation pathways
• Neuroprotective agents: Target multiple pathways
• Repositioned drugs: FDA-approved compounds

Animal Models in Detail

Mouse Models

Transgenic approaches:

• Neuron-specific promoters (TH, Synapsin, CamKII)
• Wild-type SNCAIP overexpression
• Mutant SNCAIP lines
• Conditional expression systems

• Age-dependent pathology
• Motor behavioral deficits
• Cognitive impairments
• Neurochemical changes

• Lack of robust Lewy body formation
• Mild phenotype in some lines
• Species differences in aggregation

Zebrafish Models

• Transient knockdown (morpholinos)
• Stable transgenic lines
• Behavioral assays (locomotion, learning)
• Live imaging capability

Drosophila Models

• Homologous gene (Snrip)
• Pan-neuronal expression
• Behavioral readouts
• Genetic interactors

Research Techniques

Biochemical Approaches

• Co-immunoprecipitation studies
• Mass spectrometry proteomics
• Post-translational modification analysis
• Ubiquitination assays
• Protease susceptibility assays

Imaging Techniques

• Confocal microscopy
• Electron microscopy
• Super-resolution imaging (STED, PALM)
• Live cell imaging
• PET imaging

Functional Studies

• Patch-clamp electrophysiology
• Calcium imaging
• Neurotransmitter measurement (HPLC, ELISA)
• Behavioral testing (rotarod, cylinder, gait)

Evolutionary Conservation

Species Distribution

• Humans: Full-length synphilin-1 (777 aa)
• Rodents: High conservation (>90%)
• Birds: Functional orthologs present
• Fish: Zebrafish model organisms
• Invertebrates: Drosophila homolog

Functional Conservation

• Alpha-synuclein binding conserved
• Ubiquitination sites preserved
• Tissue expression patterns maintained
• Subcellular localization similar

Clinical Considerations

Diagnosis

• Genetic testing available (clinical labs)
• Protein markers in development
• Clinical criteria remain primary
• Differential diagnosis important

Patient Management

• Symptomatic treatment focus
• Genetic counseling for families
• Clinical trial eligibility assessment
• Supportive care strategies
• multidisciplinary approach

Future Directions

Research Priorities

Emerging Technologies

• Cryo-EM structure determination
• Single-cell omics approaches
• Brain organoid models
• Advanced in vivo imaging
• Gene editing advances
• Alpha-synuclein aggregation blockers: May act on SNCAIP interaction
• SIAH-1 modulators: Alter degradation pathways
• Neuroprotective agents: Target multiple pathways

Research Models

Cellular Models

• Transient transfection: Overexpression studies
• Stable cell lines: Long-term expression
• Primary neurons: Neuronal function
• iPSC-derived models: Patient-specific disease modeling

Animal Models

• Transgenic mice: SNCAIP overexpression
• Double transgenic: SNCA and SNCAIP
• Knockout models: Loss-of-function studies
• Viral models: AAV-mediated expression

Phenotypic Findings

Animal models reveal:

• Alpha-synuclein aggregation
• Movement abnormalities
• [Neurodegeneration](/diseases/neurodegeneration) Synaptic dysfunction

Cross-Links

• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Autophagy](/mechanisms/autophagy)
• [SNARE Complex](/mechanisms/snare-complex)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)

See Also

• [Genes Section](/genes)
• [Synaptic Proteins](/proteins)
• [Parkinson's Disease Genes](/diseases/parkinsons-genes)
• [Protein Aggregation Pathways](/mechanisms/protein-aggregation-pathways)

External Links

• [NCBI Gene: SNCAIP](https://www.ncbi.nlm.nih.gov/gene/10407)
• [UniProt: O60341](https://www.uniprot.org/uniprot/O60341)
• [Ensembl: ENSG00000145341](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145341)
• [OMIM: 603516](https://www.omim.org/entry/603516)
• [PubMed: SNCAIP](https://pubmed.ncbi.nlm.nih.gov/?term=sncaip+parkinson)

Mitochondrial Dysfunction

Synphilin-1 affects mitochondrial function in multiple ways[@yan2018]:

• Mitochondrial dynamics: Alters fission/fusion balance
• Respiratory function: Impairs complex I activity
• Calcium handling: Disrupts mitochondrial calcium buffering
• Apoptosis pathway: Modulates programmed cell death

ROS Production

Synphilin-1 expression affects reactive oxygen species:

• Increased ROS generation
• Oxidative stress accumulation
• DNA damage
• Lipid peroxidation

Mitochondrial Quality Control

• Mitophagy: Impaired clearance of damaged mitochondria
• Biogenesis: Reduced mitochondrial renewal
• Transport: Defective mitochondrial trafficking

Synaptic Dysfunction

Synphilin-1 plays important roles at the synapse[@engel2006][@sato2019]:

Neurotransmitter Release

• Altered dopamine release
• Impaired synaptic vesicle cycling
• Reduced release probability
• Abnormal vesicle replenishment

SNARE Complex Effects

Synphilin-1 modulates the SNARE machinery[@rubio2012]:

• Direct interaction with SNAP25
• Assembly of ternary complexes
• Calcium-dependent regulation
• Release site availability

Cellular Stress Responses

Endoplasmic Reticulum Stress

Synphilin-1 accumulation triggers ER stress:

• Unfolded protein response activation
• CHOP expression
• Caspase activation
• Cell death execution

Lysosomal Dysfunction

• Cathepsin activation
• Membrane permeabilization
• Autophagosome accumulation
• Failed cargo degradation

Neuroinflammation

Synphilin-1 pathology affects glial cells:

Microglial Activation

• Pro-inflammatory cytokine release
• MHC class II upregulation
• NADPH oxidase activation
• Chronic neuroinflammation

Astrocyte Responses

• Reactive astrogliosis
• Altered glutamate uptake
• Impaired potassium buffering
• Trophic factor secretion

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SNCAIP Gene discovered through SciDEX knowledge graph analysis: